ImageneBio, Inc. — Director's Dealing 2021

Mar 26, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-03-25

Reporting Person: Atlas Venture Fund XI, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates XI, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates XI, LLC (10% Owner)
Reporting Person: Atlas Venture Fund X, L.P. (10% Owner)
Reporting Person: ATLAS VENTURE ASSOCIATES X, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates X, LLC (10% Owner)
Reporting Person: Atlas Venture Opportunity Fund I, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates Opportunity I, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates Opportunity I, LLC (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	169095	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (1327927)		Indirect
Series A-1 Preferred Stock	$		Common Stock (1573682)		Indirect
Series A-2 Preferred Stock	$		Common Stock (1099118)		Indirect
Series B Preferred Stock	$		Common Stock (749634)		Indirect

Footnotes

F1: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("Associates XI") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("Associates XI LLC") is the general partner of Associates XI. Each of Associates XI and Associates XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas XI, except to the extent of its pecuniary interest therein, if any.

F2: The Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") is convertible into Common Stock on a one-for-7.154 basis into the number of shares of Common Stock shown in Column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock has no expiration date.

F3: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.

F4: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.